You are here

  • Home
  • Archive
  • Volume 95, Issue 11
  • Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse

Responses

Article menu
Neuro-inflammation
Original research
Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse
Compose a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on: 16 October 2024
    Optimizing Oral Corticosteroid Regimens for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) Onset
    • Mohsen Salimi, MD Student Research Committee, Shiraz University of Medical Science, Shiraz, Iran

    Dear Editor,
    I am writing to offer a comprehensive analysis and reflection on the manuscript titled "Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse" (1). This study, which delves into the intricate nuances of managing MOGAD, presents crucial findings that could significantly impact clinical practice and patient outcomes.
    The complexity of MOGAD lies not only in its diverse clinical presentations but also in its variable response to treatment modalities. As highlighted in the manuscript's introduction, MOGAD encompasses a spectrum of neurological manifestations, ranging from optic neuritis and transverse myelitis to acute disseminated encephalomyelitis. The recent establishment of consensus diagnostic criteria marks a pivotal advancement in early recognition and intervention, underscoring the urgency for evidence-based therapeutic strategies.
    One of the most compelling aspects of the study is its exploration of the optimal corticosteroid regimen at MOGAD onset, aiming to delay the time to first relapse (TTFR) while minimizing cumulative corticosteroid exposure. By retrospectively analyzing data from a multicenter cohort comprising 109 patients, the authors meticulously assessed the relationship between corticosteroid dosage and taper duration and the subsequent risk of relapse. The utilization of Cox proportional hazards models, along...

    Show More
    Conflict of Interest:
    None declared.